Johnson & Johnson : 2022 Fourth-Quarter Press Release & Supplemental Schedules

FOR IMMEDIATE RELEASE

• 2022 Fourth-Quarter reported sales decline of 4.4% to $23.7 Billion primarily driven by unfavorable foreign exchange and reduced COVID-19 Vaccine sales vs. prior year. Operational growth excluding COVID-19 Vaccine of 4.6%*
• 2022 Fourth-Quarter earnings per share (EPS) of $1.33 decreasing 24.9% and adjusted EPS of $2.35 increasing by 10.3%*

__________________________________________________________________________________________

• 2022 Full-Year reported sales growth of 1.3% to $94.9 Billion primarily driven by strong commercial execution partially offset by unfavorable foreign exchange. Operational growth of 6.1%*
• 2022 Full-Year earnings per share (EPS) of $6.73 decreasing 13.8% and adjusted EPS of $10.15 increasing by 3.6%*

__________________________________________________________________________________________

• Company guides 2023 adjusted operational sales growth excluding COVID-19 Vaccine of 4.0%* and adjusted operational EPS of $10.50, reflecting growth of 3.5%*

New Brunswick, N.J. (January 24, 2023) - Johnson & Johnson (NYSE: JNJ) today announced results for fourth- quarter and full year 2022. "Our full year 2022 results reflect the continued strength and stability of our three business segments, despite macroeconomic challenges," said Joaquin Duato, Chairman of the Board and Chief Executive Officer. "I am inspired by our employees who make a difference in the health and lives of people around the world every day. As we look ahead to 2023, Johnson & Johnson is well-positioned to drive near-term growth, while also investing strategically to deliver long-term value."

OVERALL FINANCIAL RESULTS

			Q4
($ in Millions, except EPS)		2022	2021	% Change
Reported Sales	$23,706	$24,804	(4.4)%
Net Earnings	$3,520	$4,736	(25.7)%
EPS (diluted)	$1.33	$1.77	(24.9)%

Full Year

2022	2021	% Change
$94,943	$93,775	1.3%
$17,941	$20,878	(14.1)%
$6.73	$7.81	(13.8)%

			Q4
Non-GAAP* ($ in Millions, except EPS)		2022	2021	% Change
Operational Sales1,2				0.9%
Adjusted Operational Sales1,3				0.8%
Adjusted Net Earnings1,4	$6,218	$5,678	9.5%
Adjusted EPS (diluted)1,4	$2.35	$2.13	10.3%

Full Year

2022	2021	% Change
		6.1%
		6.2%
$27,038	$26,195	3.2%
$10.15	$9.80	3.6%

1. Non-GAAPfinancial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2. Excludes the impact of translational currency
3. Excludes the net impact of acquisitions and divestitures and translational currency
4. Excludes intangible amortization expense and special items

Note: values may have been rounded

REGIONAL SALES RESULTS

	Q4										% Change
	($ in Millions)		2022			2021			Reported		Operational1,2		Currency		Adjusted
									Operational1,3
	U.S.	$12,516		$12,163		2.9%	2.9	-	2.7
	International	11,190		12,641		(11.5)	(1.1)	(10.4)	(1.0)
	Worldwide	$23,706		$24,804		(4.4)%	0.9	(5.3)	0.8

	Full Year										% Change
	($ in Millions)		2022			2021			Reported		Operational1,2		Currency		Adjusted
									Operational1,3
	U.S.	$48,580		$47,156		3.0%	3.0	-	3.0
	International	46,363		46,619		(0.6)%	9.1	(9.7)	9.3
	Worldwide	$94,943		$93,775		1.3%	6.1	(4.8)	6.2

1. Non-GAAPfinancial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2. Excludes the impact of translational currency
3. Excludes the net impact of acquisitions and divestitures and translational currency

Note: Values may have been rounded

SEGMENT SALES RESULTS

	Q4										% Change
	($ in Millions)		2022			2021			Reported		Operational1,2		Currency			Adjusted
										Operational1,3
	Consumer Health4	$3,767		$3,728		1.0%	6.4	(5.4)		6.4
	Pharmaceutical4	13,163		14,217		(7.4)	(2.5)	(4.9)		(2.3)
	MedTech	6,776		6,859		(1.2)	4.9	(6.1)		4.4
	Worldwide	$23,706		$24,804		(4.4)%	0.9	(5.3)		0.8

	Full Year										% Change
	($ in Millions)		2022			2021			Reported		Operational1,2		Currency			Adjusted
										Operational1,3
	Consumer Health4	$14,953		$15,035		(0.5)%	3.6	(4.1)		3.9
	Pharmaceutical4	52,563		51,680		1.7	6.7	(5.0)		6.8
	MedTech	27,427		27,060		1.4	6.2	(4.8)		6.1
	Worldwide	$94,943		$93,775		1.3%	6.1	(4.8)		6.2

1. Non-GAAPfinancial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2. Excludes the impact of translational currency
3. Excludes the net impact of acquisitions and divestitures and translational currency
4. Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes
   Note: Values may have been rounded

FULL YEAR 2022 SEGMENT COMMENTARY:

Adjusted operational sales* reflected below excludes the net impact of acquisitions and divestitures and translational currency.

Consumer Health

Consumer Health worldwide adjusted operational sales increased 3.9%* predominately driven by over-the- counter (OTC) products. Major contributors to growth in OTC were TYLENOL and MOTRIN analgesics, as well as upper respiratory products and digestive health products in the international markets. Additionally, Skin Health/Beauty adjusted operational growth was primarily driven by NEUTROGENA outside the U.S. Growth was partially offset by Oral Care in the international markets.

Pharmaceutical

Pharmaceutical worldwide adjusted operational sales grew 6.8%*, driven by DARZALEX (daratumumab), a biologic for the treatment of multiple myeloma, STELARA (ustekinumab), a biologic for the treatment of a number of immune-mediated inflammatory diseases, ERLEADA (apalutamide), a next-generation androgen receptor inhibitor for the treatment of patients with prostate cancer, TREMFYA (guselkumab), a biologic for the treatment of adults living with moderate to severe plaque psoriasis, and for adults with active psoriatic arthritis, and INVEGA SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults. This growth was partially offset by declines in sales of REMICADE (infliximab), a biologic approved for the treatment of several immune-mediated inflammatory diseases, IMBRUVICA (ibrutinib), an oral, once daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer, and ZYTIGA (abiratone acetate), an oral, once daily

medication for use in combination with prednisone for the treatment of metastatic castration-resistant prostate cancer.

MedTech

MedTech worldwide adjusted operational sales grew 6.1%*, driven primarily by electrophysiology products in Interventional Solutions, contact lenses in Vision, and wound closure products in General Surgery.

NOTABLE NEW ANNOUNCEMENTS IN THE QUARTER:

The information contained in this section should be read in conjunction with Johnson & Johnson's other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov,www.jnj.comor on request from Johnson & Johnson. The reader is also encouraged to review all other news releases and information available in the Investors section of the company's website at news releases, as well as www.factsabouttalc.com,www.factsaboutourprescriptionopioids.com, and www.LTLManagementInformation.com.

	DePuy Synthes Receives FDA Clearance for TELIGEN System	Press
	Release
Regulatory	U.S. FDA Approves TECVAYLI (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody	Press
for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma	Release
	Janssen Submits Biologics License Application to U.S. FDA for Talquetamab for the Treatment of	Press
	Patients with Relapsed or Refractory Multiple Myeloma	Release
	New TREMFYA (guselkumab) Data Shows an Overall Clinical Response Rate of Approximately	Press
	80 Percent in a Phase 2b Induction Study of Adults with Moderately to Severely Active Ulcerative
	Release
	Colitis
	Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with	Press
	Clinical and Real-World Data Across Innovative Pipeline and Distinguished Portfolio	Release
	Late-Breaking Data from Pivotal Phase 3 PRECISION Study Demonstrates Significant and	Press
	Sustained Effect of Aprocitentan on Lowering Blood Pressure for Patients with Difficult-to-Control
	Release
Data	Hypertension
Release
New TREMFYA (guselkumab) Post-Hoc Analysis Reveals Active Psoriatic Arthritis Patients With	Press
	Early Efficacy Had Meaningful Long-Term Improvement in Health-Related Quality of Life	Release
	New TREMFYA (guselkumab) Post-Hoc Analysis Reveals Early Efficacy Predicted Longer-Term	Press
	Efficacy And Sustained Achievement Among A Diverse Active Psoriatic Arthritis Patient
	Release
	Population
	CERENOVUS Reveals Positive Outcomes with Thrombectomy in Global Registry Studying	Press
	Stroke-Inducing Blood Clots	Release
	Johnson & Johnson Names CEO Joaquin Duato as Chairman of the Board	Press
	Release
Other
Johnson & Johnson Completes Acquisition of Abiomed	Press
	Release

FULL-YEAR 2023 GUIDANCE:

Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP.

($ in Billions, except EPS)	January 2023
Adjusted Operational Sales1,2,5	3.5% - 4.5% / 4.0%
Change vs. Prior Year / Mid-point
Operational Sales2,5/ Mid-point2,5	$96.9B - $97.9B / $97.4B
Change vs. Prior Year / Mid-point	4.5% - 5.5% / 5.0%
Estimated Reported Sales3,5/ Mid-point3,5	$96.9B - $97.9B / $97.4B
Change vs. Prior Year / Mid-point	4.5% - 5.5% / 5.0%
Adjusted Operational EPS (Diluted)2,4/ Mid-point2,4	$10.40 - $10.60 / $10.50
Change vs. Prior Year / Mid-point	2.5% - 4.5% / 3.5%
Adjusted EPS (Diluted)3,4 / Mid-point3,4	$10.45 - $10.65 / $10.55
Change vs. Prior Year / Mid-point	3.0% - 5.0% / 4.0%

1. Non-GAAPfinancial measure; excludes the net impact of acquisitions and divestitures
2. Non-GAAPfinancial measure; excludes the impact of translational currency
3. Calculated using Euro Average Rate: January 2023 = $1.08 (Illustrative purposes only)
4. Non-GAAPfinancial measure; excludes intangible amortization expense and special items 5 Excludes COVID-19 Vaccine
   Note: percentages may have been rounded

Other modeling considerations will be provided on the webcast.

WEBCAST INFORMATION:

Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website. A replay and podcast will be available approximately two hours after the live webcast in the Investors section of the company's website at events-and-presentations.